NRx Pharmaceuticals says FDA reclassified ANDA amendment as minor
NRx Pharmaceuticals said the FDA reclassified its ANDA amendment as a Minor Amendment and set a GDUFA goal date of Nov. 10, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.